AVXL Anavex Life Sciences Corp.

NASDAQ
$2.38

Anavex Life Sciences Corp. (AVXL) is expected to report earnings on December 2, 2026, before the market open. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -29.4% since its last earnings release on August 25, 2026.

Anavex Life Sciences Beat Consensus Estimates
Tuesday, August 25, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Sep 2026
Dec 2
Wednesday · 8:00 AM ET
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.